Warren M, et al. - Researchers assessed the efficacy and safety of semaglutide vs comparators in non-elderly (<65 years) and elderly (≥65 years) patients with type 2 diabetes (T2D) across the SUSTAIN 1-5 trials. For this analysis, patients were randomized to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin. Change in HbA1c was the primary objective whereas changes in body weight and safety were the secondary objectives. The findings demonstrated that semaglutide had a comparable efficacy and safety profile in non-elderly and elderly patients across the SUSTAIN 1-5 trials, making it a successful treatment alternative for elderly patients with T2D.